Mineralys Therapeutics holds routine annual meeting, elects three directors

Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• low

  Stockholders elected three Class III directors to three-year terms expiring in 2029: Srinivas Akkaraju, Brian Taylor Slingsby, and Daphne Karydas. All nominees received majority support.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young LLP ratified as independent auditor for fiscal 2026 with 72.6 million votes in favor, representing near-unanimous shareholder approval.

  Item 5.07 verify on EDGAR →